SCHEMBL17601239

SCHEMBL17601239

COc1cc2nc(Cl)c(C=O)cc2cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.59
CYP2C19 P33261 2/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
ALDH1A1 P00352 9/20 0.53
KDM4E B2RXH2 5/20 0.45
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
MPI P34949 1/20 0.45
PGK1 P00558 4/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
GSK3B P49841 1/20 0.41
MAP4K2 Q12851 1/20 0.41
ERN1 O75460 2/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30623193 1.00 CYP1A2 (0.59) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL9245838 0.90 CYP3A4 (0.63) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL17603172 0.86 ALDH1A1 (0.45) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL26417909 0.85 ERN1 (0.45) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL16896834 0.85 CYP1A2 (0.56) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL4742361 0.85 CYP1A2 (0.56) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL30623288 0.84 CYP1A2 (0.55) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL17603143 0.84 CYP1A2 (0.55) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL5860050 0.82 CYP1A2 (0.56) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1
SCHEMBL6304525 0.81 CYP1A2 (0.68) CYP1A2CYP2C19CYP3A4CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275715-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2025-04-15 US disclosed
US-20240150319-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2024-05-09 US disclosed
CN-117695280-A Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors 福马治疗股份有限公司 2024-03-15 CN disclosed
CN-111909130-B Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors 福马治疗股份有限公司 2023-10-31 CN disclosed
EP-4257131-A2 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS Forma Therapeutics, Inc. (US) 2023-10-11 EP disclosed
EP-4257131-A2 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS Forma Therapeutics, Inc. (US) 2023-10-11 EP disclosed
EP-3733662-B1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS INC (US) 2023-06-07 EP disclosed
EP-3733662-B1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS INC (US) 2023-06-07 EP disclosed
US-20230125739-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2023-04-27 US disclosed
US-20230125739-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2023-04-27 US disclosed
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
US-20160083349-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
US-20160083366-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
US-20160083366-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
US-20160083367-A1 PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
US-20160083367-A1 PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
US-20160083366-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed
WO-2016044782-A1 PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125739-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH2 CYP1A2 761/4885CYP2C19 2065/4885CYP3A4 2681/4885
US-12275715-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors IDH1, IDH3A, IDH2 CYP1A2 761/4885CYP2C19 2065/4885CYP3A4 2681/4885
US-20160083367-A1 PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH3B CYP1A2 1607/4885CYP2C19 2831/4885CYP3A4 2620/4885
US-20160083349-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH3A, IDH1, IDH2 CYP1A2 683/4885CYP2C19 2081/4885CYP3A4 2424/4885
US-20160083366-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH2 CYP1A2 761/4885CYP2C19 2065/4885CYP3A4 2681/4885
US-20240150319-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH2 CYP1A2 761/4885CYP2C19 2065/4885CYP3A4 2681/4885
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH3B CYP1A2 1582/4885CYP2C19 2806/4885CYP3A4 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.